Lilly/Amylin Submit Exenatide For Type 2 Diabetes; Could Be Insulin Alternative
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will likely target patients on oral diabetes medications who would normally take insulin. Priority review for the first-in-class incretin mimetic would set a user fee goal date of Dec. 30.